Rasmus Røjkjaer

Suggest Changes
Learn More
BACKGROUND Recombinant coagulation factor VIIa (rFVIIa) is generally accepted for treatment of patients with inhibitor-complicated hemophilia. Recently, rFVIIa variants with a specific enhancement of(More)
  • 1